Flash Finance

Divi's Laboratories LimitedDIVISLABCorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹9,144.50
MCap ₹242,758 Cr · P/E 82.5
Divi's Laboratories Limited — Stock analysis & AI research Divi's Laboratories Limited — Seasonality — best & worst months Divi's Laboratories Limited — Technical indicators & charts Divi's Laboratories Limited — Technical setup — score, trend, support & resistance Divi's Laboratories Limited — Live exchange announcements
📋 High ROCE Stocks📋 High Operating Margin Stocks📋 High Interest Coverage Stocks📋 Stocks With Strong Quarterly Results📋 Low Debt Stocks📋 Large Cap Stocks List 📈 SuperTrend Bearish Signal📈 Multi-Timeframe Bullish Stocks ⚖️ vs Neuland Laboratories⚖️ vs Jubilant Pharmova 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹2,974 Cr
Sales · Jun 2026
+26.2% YoY
₹1,240 Cr
Operating Profit · Jun 2026
+66.9% YoY
41.7%
OPM % · Jun 2026
+32.4% YoY
₹891 Cr
Net Profit · Jun 2026
+60.0% YoY
₹33.55
EPS · Jun 2026
+59.9% YoY

📝 Divi's Laboratories Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Divi's Laboratories Limited reported revenue of ₹2,974 crore for the quarter ended June 2026 (Q1 FY27), up 26.2% from ₹2,357 crore in the same quarter last year, and up 6.5% sequentially over the March 2026 quarter.

Net profit rose 60.0% year-on-year to ₹891 crore, from ₹557 crore. Earnings per share (EPS) came in at ₹33.55.

Operating profit stood at ₹1,240 crore — an operating margin (OPM) of 41.7%, compared with 31.5% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Divi's Laboratories Limited posted revenue of ₹10,388 crore, a growth of 12.9% over FY25, with a net profit of ₹2,607 crore (up 18.0% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹11,005 crore with a net profit of ₹2,941 crore.

Valuation snapshot

At the current price of ₹9,144.50, DIVISLAB has a market capitalisation of ₹242,758 crore and a trailing P/E of about 82.5.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 2nd-largest of the 31 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 51.88%, foreign institutional investors (FIIs) 20.38%, domestic institutional investors (DIIs) 19.17%, public shareholders 8.58% of Divi's Laboratories Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹242,758 Cr
Current Price ?
₹9,144.5
P/E ?
82.54above ind
Industry P/E ?
35.00
P/B ?
14.53
P/S ?
22.06
P/FCF ?
1,244.91
Enterprise Value ?
₹242,758 Cr
EV/EBITDA ?
60.92
PEG ?
5.90
Earnings Yield ?
1.4%
Dividend Yield ?
0.32%
Profitability & Returns
Sales (TTM) ?
₹11,005 Cr
OPM ?
36.2%
Profit after tax (TTM) ?
₹2,941 Cr
EPS (TTM) ?
₹110.79
ROCE ?
22.0%
ROE ?
17.6%
ROA ?
14.7%
Growth
Sales — latest qtr ?
₹2,974 Cr
PAT — latest qtr ?
₹891 Cr
YoY qtr sales growth ?
26.2%
YoY qtr profit growth ?
60.0%
Sales growth (3y) ?
11%
Sales growth (5y) ?
9%
Profit growth (3y) ?
14%
Profit growth (5y) ?
6%
Financial Health
Debt ?
₹0 Cr
Debt to Equity ?
0.00
Interest Coverage ?
131.6
Current Ratio ?
N/A
Ownership
Promoter holding ?
51.88%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
26.2%
Return 6 months ?
46.8%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 1,6901,9081,7301,8681,8082,2592,0632,3022,2972,5362,3572,6602,5782,7932,974 +26.2% +6.5%
Operating Profit 4094894914744917176217297478817438959079431,240 +66.9% +31.5%
Other Income 11666808594797910582871191461315463 -47.1% -59.1%
Interest 000102010038666 +100.0% +0.0%
Depreciation 878793949594979899107112113116120132 +17.9% +10.0%
Profit Before Tax 4394684784644907006037357308617479207989711,165 +56.0% +20.0%
Net Profit 311319345342358531430518594667557696598756891 +60.0% +17.9%
EPS 11.7112.0112.9912.8913.5019.9916.1819.5122.3825.1320.9826.2222.5328.4833.55 +59.9% +17.8%
OPM % 24.2% 25.6% 28.4% 25.4% 27.2% 31.7% 30.1% 31.7% 32.5% 34.7% 31.5% 33.6% 35.2% 33.8% 41.7% +32.4% +23.4%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹9,198 Cr ₹10,388 Cr ₹11,005 Cr +12.9%
Operating Profit ₹2,978 Cr ₹3,488 Cr ₹3,985 Cr +17.1%
OPM % 32.38% 33.58% 36.21% +3.7%
NPM % 24.02% 25.10% 26.72% +4.5%
Other Income ₹353 Cr ₹432 Cr ₹376 Cr +22.4%
Depreciation ₹401 Cr ₹461 Cr ₹481 Cr +15.0%
Interest ₹1 Cr ₹23 Cr ₹26 Cr +2200.0%
EBIT ₹2,577 Cr ₹3,027 Cr ₹3,504 Cr +17.5%
PBT ₹2,929 Cr ₹3,436 Cr ₹3,854 Cr +17.3%
Tax ₹390 Cr — ₹274 Cr —
Net Profit ₹2,209 Cr ₹2,607 Cr ₹2,941 Cr +18.0%
EPS ₹83.20 ₹98.21 ₹110.78 +18.0%
Material Cost ₹1,835 Cr — ₹1,495 Cr —
Employee Cost ₹581 Cr — ₹397 Cr —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 53535353 +0.0%
Reserves 12,65213,43114,84216,658 +12.2%
Borrowings 0020 -100.0%
Other Liabilities 1,6471,8781,9273,243 +68.3%
Total Liabilities 14,35215,36216,82419,954 +18.6%
Fixed Assets 4,7194,7375,4406,520 +19.9%
CWIP 2127781,0222,113 +106.8%
Investments 84897276 +5.6%
Other Assets 9,3379,75810,29011,245 +9.3%
Total Assets 14,35215,36216,82419,954 +18.6%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 2,4471,2661,6502,711 +64.3%
Cash from Investing Activity -2,707-268-803-2,218 -176.2%
Cash from Financing Activity -796-798-797-802 -0.6%
Net Cash Flow -1,05620050-309 -718.0%
Free Cash Flow 1,975264213195 -8.5%
CFO/OP 124%75%83%102% +22.9%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Days Payable 889486108 +25.6%
Debtor Days 94108113113 +0.0%
Inventory Days 329347296337 +13.9%
Cash Conversion Cycle 335361323343 +6.2%
Working Capital Days 190207193198 +2.6%
ROCE % 19%16%21%22% +4.8%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 51.88%51.88%51.88%51.88%51.88% +0.0%
FIIs 19.74%19.39%20.08%20.29%20.38% +0.4%
DIIs 18.96%19.68%19.18%19.13%19.17% +0.2%
Government 0.09%0.09%0.09%0.09%— —
Public 9.32%8.96%8.75%8.61%8.58% -0.3%
No. of Shareholders 2,59,8252,49,6342,33,8442,28,0062,32,256 +1.9%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 ASTRAZEN AstraZeneca Pharma ₹6,755.00 16,888 99.6 2,432 170 9.4% 7.0% 32.7% 62.1% 29.7% -32.1%
❓ Frequently asked questions
What was Divi's Laboratories Limited's revenue in Q1 FY27?
Divi's Laboratories Limited reported revenue of ₹2,974 crore for the quarter ended June 2026 (Q1 FY27), up 26.2% from ₹2,357 crore in the same quarter last year, and up 6.5% sequentially over the March 2026 quarter.
What was Divi's Laboratories Limited's net profit in Q1 FY27?
Net profit rose 60.0% year-on-year to ₹891 crore, from ₹557 crore. Earnings per share (EPS) came in at ₹33.55.
What is DIVISLAB's market capitalisation and P/E ratio?
At the current price of ₹9,144.50, DIVISLAB has a market capitalisation of ₹242,758 crore and a trailing P/E of about 82.5.
Who owns Divi's Laboratories Limited? (shareholding pattern)
As of Sep 2026, promoters held 51.88%, foreign institutional investors (FIIs) 20.38%, domestic institutional investors (DIIs) 19.17%, public shareholders 8.58% of Divi's Laboratories Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI